Information Provided By: 
Fly News Breaks for February 15, 2018
PBYI
Feb 15, 2018 | 05:18 EDT
Citi analyst Yigal Nochomovitz added Puma Biotechnology to his firm's U.S. Focus List citing "high conviction" on the name and the Nerlynx launch in breast cancer. Even with yesterday's 11% rally, the stock is trading at roughly 10 times the 2018 consensus Nerlynx revenue estimate of $220M and two times a peak U.S. sales estimate of $1.1B, Nochomovitz tells investors in a research note . He believes Puma's U.S. opportunity alone is worth $90 per share. The analyst keeps a Buy rating on the shares with a $146 price target.
News For PBYI From the Last 2 Days
There are no results for your query PBYI
